Physician profile
Robert Yang
NPI 1619043163
$653.07
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $176 · 2021: $210 · 2022: $13.68.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $169.51 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $86.16 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $83.05 | 2019-2020 | |
| Glaxosmithkline, LLC. | $65.86 | 2019-2020 | |
| Allergan, INC. | $43.07 | 2020 | |
| Abbvie INC. | $34.87 | 2019 | |
| Janssen Pharmaceuticals, INC | $32.95 | 2019 | |
| Neotract INC. | $30.70 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.69 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.88 | 2020 | |
| Sanofi-Aventis U.S. LLC | $16.93 | 2020 | |
| Lilly USA, LLC | $15.92 | 2019 | |
| Gilead Sciences, INC. | $13.68 | 2022 | |
| Pfizer INC. | $12.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.